Acar, AyşeGüzel, SavaşSarıfakıo?lu, Ayşe BanuÇelik Güzel, EdaYıldırım Güzelant, AliyeKaradağ, CeydaKızıler, Lebriz2022-05-112022-05-1120160770-31981434-9949https://doi.org/10.1007/s10067-016-3240-yhttps://hdl.handle.net/20.500.11776/5270Rheumatoid arthritis (RA) is a chronic, inflammatory, and autoimmune disease that can cause permanent joint damage. In our study, we aim to analyze the change in calprotectin levels following the low-density exercise levels applied to the patients with RA. Twenty-eight patients with RA and 30 healthy controls were included in this study. To evaluate the activity of disease in RA, scores of disease activity that has increased (DAS-28) are figured. Calprotectin, nitric oxide (NO), white blood cell (WBC) count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and rheumatoid factor (RF) levels are tested as the laboratory evaluation. Calprotectin, NO, CRP, ESR, WBC, and RF levels were significantly higher in the patient group compared to the control group (p < 0.01, p < 0.001, p < 0.01, p < 0.01, p < 0.01, and p < 0.05, respectively). In correlation analysis applied to the patient group with RA, there has been determined a positive relation with calprotectin, and DAS-28, CRP, NO, RF, and WBC (p < 0.001, p < 0.05, p < 0.001, p < 0.05, and p < 0.05, respectively). In result of the low-density exercise treatment applied to patients with RA for 8 weeks, there has been determined a significant decrease in calprotectin, DAS-28, NO, CRP, ESR, and RF levels (p < 0.05, p < 0.001, p < 0.01, p < 0.05, p < 0.05, and p < 0.05, respectively). As a result, a significant relation is found between RA disease activity and calprotectin levels and other inflammatory parameters. At the same time, it shows that calprotectin which is a significant indicator of local inflammation can be used as a good identifier in following up exercise treatment.en10.1007/s10067-016-3240-yinfo:eu-repo/semantics/closedAccessCalprotectinDisease activityExercise treatmentNitric oxideRheumatoid arthritisC-Reactive ProteinDisease-ActivityNitric-OxideSynovial-FluidSerum-LevelsPlasmaInflammationMuscleMethotrexateExpressionArticle351126852692Q3WOS:0003863620000082-s2.0-8496433428027094943Q2